{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:40:13Z","timestamp":1788478813687,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00045"],"award-info":[{"award-number":["75N93019C00045"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00014"],"award-info":[{"award-number":["75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00045"],"award-info":[{"award-number":["75N93019C00045"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00014"],"award-info":[{"award-number":["75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00014"],"award-info":[{"award-number":["75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00045"],"award-info":[{"award-number":["75N93019C00045"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00045"],"award-info":[{"award-number":["75N93019C00045"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00014"],"award-info":[{"award-number":["75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00045"],"award-info":[{"award-number":["75N93019C00045"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00014"],"award-info":[{"award-number":["75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00045"],"award-info":[{"award-number":["75N93019C00045"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Viruses"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many different platforms have been used to develop highly protective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans. However, protection has eroded over time due to the emergence of antigenically diverse viral variants, especially the Omicron subvariants. One successful platform for the generation of SARS-CoV-2 vaccines are recombinant spike protein vaccines, of which two are licensed in the United States and Europe. Typically, purified recombinant protein antigens are poorly immunogenic and adjuvants must be included in the formulation. Here, we adjuvanted recombinant ancestral SARS-CoV-2 Wuhan-Hu-1 spike proteins with an emulsion formulation combined with synthetic Toll-like receptor (TLR) 4 and 7\/8 agonists. This combination led to the induction of a Th1-skewed immune response that included high titers of antibodies against Wuhan-Hu-1 spike. These serum antibodies included neutralizing and cross-reactive antibodies that recognized the spike from multiple SARS-CoV-2 variants, as well as the receptor binding domain (RBD) from SARS-CoV-1. Despite an absence of robust cross-neutralization, vaccination against Wuhan-Hu-1 spike in the context of TLR-containing emulsions provided complete cross-protection against disease from a lethal challenge with XBB.1 in a stringent K18-hACE2 mouse model. We believe that the combination of recombinant spike antigens with TLR agonist-based emulsion formulations could lead to the development of next-generation SARS-CoV-2 vaccines that provide significant protection from future emerging variants.<\/jats:p>","DOI":"10.1038\/s44298-024-00038-0","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T10:04:25Z","timestamp":1722938665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1"],"prefix":"10.1038","volume":"2","author":[{"given":"Stephanie K.","family":"Lathrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Siram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Andreata-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah D.","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara J.","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gagandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Burkhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay T.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"38_CR1","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect. Dis. 22, 1293\u20131302 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"38_CR2","doi-asserted-by":"publisher","unstructured":"Krammer, F. The role of vaccines in the COVID-19 pandemic: what have we learned? Semin Immunopathol. https:\/\/doi.org\/10.1007\/s00281-023-00996-2 (2023).","DOI":"10.1007\/s00281-023-00996-2"},{"key":"38_CR3","unstructured":"CDC COVID Data Tracker, https:\/\/covid.cdc.gov\/covid-data-tracker\/#vaccinations_vacc-people-booster-percent-pop5."},{"key":"38_CR4","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433 e2413 (2022).","journal-title":"Cell"},{"key":"38_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2189885","volume":"19","author":"L Stertman","year":"2023","unstructured":"Stertman, L. et al. The Matrix-M adjuvant: A critical component of vaccines for the 21(st) century. Hum Vaccin Immunother 19, 2189885 (2023).","journal-title":"Hum Vaccin Immunother"},{"key":"38_CR6","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","volume":"29","author":"S Morel","year":"2011","unstructured":"Morel, S. et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29, 2461\u20132473 (2011).","journal-title":"Vaccine"},{"key":"38_CR7","doi-asserted-by":"publisher","unstructured":"Short, K. K. et al. Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and alpha-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine. Pharmaceutics 14, https:\/\/doi.org\/10.3390\/pharmaceutics14071455 (2022).","DOI":"10.3390\/pharmaceutics14071455"},{"key":"38_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev.med.56.091103.134135","volume":"56","author":"DM Skowronski","year":"2005","unstructured":"Skowronski, D. M. et al. Severe acute respiratory syndrome (SARS): a year in review. Annu Rev Med 56, 357\u2013381 (2005).","journal-title":"Annu Rev Med"},{"key":"38_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.vaccine.2007.11.054","volume":"26","author":"A Wack","year":"2008","unstructured":"Wack, A. et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26, 552\u2013561 (2008).","journal-title":"Vaccine"},{"key":"38_CR10","doi-asserted-by":"publisher","unstructured":"Francica, J. R. et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci. Transl. Med. 13, https:\/\/doi.org\/10.1126\/scitranslmed.abi4547 (2021).","DOI":"10.1126\/scitranslmed.abi4547"},{"key":"38_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29219-2","volume":"13","author":"V Pavot","year":"2022","unstructured":"Pavot, V. et al. Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. Nat. Commun. 13, 1699 (2022).","journal-title":"Nat. Commun."},{"key":"38_CR12","doi-asserted-by":"publisher","unstructured":"Kirsebom, F. C. M. et al. Effectiveness of the adjuvanted Sanofi\/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original\/Omicron BA.4-5) bivalent vaccines against hospitalisation amongst adults aged 75 years and older in England, estimated using a test-negative case control study design. medRxiv, 2023.2009.2028.23296290. https:\/\/doi.org\/10.1101\/2023.09.28.23296290 (2023).","DOI":"10.1101\/2023.09.28.23296290"},{"key":"38_CR13","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s11095-009-9859-5","volume":"26","author":"BC Baudner","year":"2009","unstructured":"Baudner, B. C. et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res. 26, 1477\u20131485 (2009).","journal-title":"Pharm. Res."},{"key":"38_CR14","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1016\/j.vaccine.2009.07.081","volume":"27","author":"SL Baldwin","year":"2009","unstructured":"Baldwin, S. L. et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27, 5956\u20135963 (2009).","journal-title":"Vaccine"},{"key":"38_CR15","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1016\/j.vaccine.2011.02.022","volume":"29","author":"S Lousada-Dietrich","year":"2011","unstructured":"Lousada-Dietrich, S. et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2\u2013a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 29, 3284\u20133292 (2011).","journal-title":"Vaccine"},{"key":"38_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep46426","volume":"7","author":"N Van Hoeven","year":"2017","unstructured":"Van Hoeven, N. et al. A Formulated TLR7\/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines. Sci. Rep. 7, 46426 (2017).","journal-title":"Sci. Rep."},{"key":"38_CR17","doi-asserted-by":"publisher","first-page":"93ra69","DOI":"10.1126\/scitranslmed.3002135","volume":"3","author":"SR Wiley","year":"2011","unstructured":"Wiley, S. R. et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci. Transl. Med. 3, 93ra69 (2011).","journal-title":"Sci. Transl. Med."},{"key":"38_CR18","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634 (2021).","journal-title":"Nature"},{"key":"38_CR19","doi-asserted-by":"publisher","unstructured":"Amanat, F. et al. Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model. mBio 12 https:\/\/doi.org\/10.1128\/mBio.02648-20 (2021).","DOI":"10.1128\/mBio.02648-20"},{"key":"38_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cpmc.100","volume":"57","author":"D Stadlbauer","year":"2020","unstructured":"Stadlbauer, D. et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr. Protoc. Microbiol. 57, e100 (2020).","journal-title":"Curr. Protoc. Microbiol."},{"key":"38_CR21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","volume":"26","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033\u20131036 (2020).","journal-title":"Nat. Med."},{"key":"38_CR22","doi-asserted-by":"publisher","first-page":"13900","DOI":"10.1021\/acs.jmedchem.3c00724","volume":"66","author":"JK Khalaf","year":"2023","unstructured":"Khalaf, J. K. et al. Diamino Allose Phosphates: Novel, Potent, and Highly Stable Toll-like Receptor 4 Agonists. J. Med. Chem. 66, 13900\u201313917 (2023).","journal-title":"J. Med. Chem."},{"key":"38_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00694-y","volume":"8","author":"SM Miller","year":"2023","unstructured":"Miller, S. M. et al. A lipidated TLR7\/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice. NPJ Vaccines 8, 97 (2023).","journal-title":"NPJ Vaccines"},{"key":"38_CR24","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1126\/science.1085952","volume":"300","author":"PA Rota","year":"2003","unstructured":"Rota, P. A. et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394\u20131399 (2003).","journal-title":"Science"},{"key":"38_CR25","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1126\/science.1222908","volume":"337","author":"C Dreyfus","year":"2012","unstructured":"Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343\u20131348 (2012).","journal-title":"Science"},{"key":"38_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103132","volume":"62","author":"W Sun","year":"2020","unstructured":"Sun, W. et al. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine 62, 103132 (2020).","journal-title":"EBioMedicine"},{"key":"38_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-022-04399-5","volume":"602","author":"JM Carreno","year":"2022","unstructured":"Carreno, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682\u2013688 (2022).","journal-title":"Nature"},{"key":"38_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/JVI.02012-06","volume":"81","author":"PB McCray Jr.","year":"2007","unstructured":"McCray, P. B. Jr. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813\u2013821 (2007).","journal-title":"J. Virol."}],"container-title":["npj Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44298-024-00038-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-024-00038-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-024-00038-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T10:15:52Z","timestamp":1722939352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44298-024-00038-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1038\/s44298-024-00038-0","relation":{},"ISSN":["2948-1767"],"issn-type":[{"value":"2948-1767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.J.B., J.T.E. and R.T. are employees of and\/or shareholders of Inimmune Corp., which owns INI-2002 and holds an exclusive license for INI-4001. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines and influenza virus therapeutics which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines. Florian Krammer is co-founder and scientific advisory board member of Castlevax. Florian Krammer has consulted for Merck, Curevac, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures, GSK, Gritstone and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}